2024-512015-47-00
Active, not recruiting
Phase 3
A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Overview
- Phase
- Phase 3
- Status
- Active, not recruiting
- Sponsor
- Incyte Corp.
- Enrollment
- 42
- Locations
- 3
- Primary Endpoint
- Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME Regimen
Overview
Brief Summary
To estimate ORR of pembrolizumab + epacadostat, pembrolizumab monotherapy, and the EXTREME regimen based on RECIST 1.1 by investigator determination.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Participants with histologically or cytologically-confirmed recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that is considered incurable by local therapies. The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
- •Measurable disease based on RECIST v1.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Adequate organ function per protocol-defined criteria.
- •Documentation of results from testing of human papilloma virus (HPV) status for oropharyngeal cancer.
- •Baseline archival tumor specimen available or willing to undergo a prestudy treatment tumor core or excisional biopsy of a tumor lesion not previously irradiated, to obtain the specimen.
Exclusion Criteria
- •Carcinoma of the nasopharynx, salivary gland, unknown primary origin, or nonsquamous histologies as primary tumors.
- •Disease progression within 6 months of completion of curatively intended systemic treatment for locoregionally advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
- •Use of protocol-defined prior/concomitant therapy.
- •Known additional malignancy that is progressing or has required active treatment within the past 3 years.
- •Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •Active autoimmune disease that has required systemic treatment in past 2 years.
- •Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
- •Known history of or is positive for active hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (defined as HCV RNA [qualitative] is detected).
Outcomes
Primary Outcomes
Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME Regimen
Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME Regimen
Secondary Outcomes
- Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab Versus the EXTREME Regimen as Measured by Number of Participants Experiencing Adverse Events (AEs)
- Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab Versus the EXTREME Regimen as Measured by Number of Participants Discontinuing Study Treatment Due to AEs
Investigators
Nirosh Naicker
Scientific
Incyte Corp.
Study Sites (3)
Loading locations...
Similar Trials
Recruiting
Phase 2
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy (PIERCE)2024-515646-16-00AGO Research GmbH42
Recruiting
Phase 2/3
A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of platinum-based doublet chemotherapy plus pembrolizumab induction treatment in patients with stage IV Non-Small Cell Lung Cancer (NSCLC)2024-515945-40-00Intergroupe Francophone De Cancerologie Thoracique1,360
Active, not recruiting
Phase 3
A study of MK7684A versus Pembrolizumab in PD-L1 Positive Metastatic NSCLC (KEYVIBE-003)2023-505362-28-00Merck Sharp & Dohme LLC156
Recruiting
Phase 2
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.2023-504832-16-00Genmab A/S102
Recruiting
Phase 3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma2024-510965-41-00AbbVie Deutschland GmbH & Co. KG94